Literature DB >> 19307978

Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.

Antonio Z Gimeno-García1, Enrique Quintero, David Nicolás-Pérez, Manuel Hernández-Guerra, Adolfo Parra-Blanco, Alejandro Jiménez-Sosa.   

Abstract

OBJECTIVE: Colonoscopy is empirically recommended as the first choice screening strategy in first-degree relatives of patients with colorectal cancer (CRC). However, this strategy is accepted by less than 40% of the risk population and two-thirds of screened individuals and renders a normal exploration. This pilot study assessed the accuracy of a latex agglutination immunochemical fecal occult blood test (LA-FOBT) for detecting advanced colorectal neoplasm (cancer or adenomatous polyps > or =1 cm in size, with villous pattern or high grade dysplasia) in asymptomatic first-degree relatives of patients with CRC.
METHODS: One hundred and sixty-nine first-degree relatives of 135 index cases were prospectively included. All participants received a sensitive LA-FOBT (hemoglobin detection limit of 50 ng/ml buffer), and were invited to undergo colonoscopy. On the whole, 116 (69%) participants returned LA-FOBT and underwent colonoscopy.
RESULTS: LA-FOBT was positive in 19 of 116 (16%) cases. Colonoscopy detected neoplasms in 49 of 116 (42%) patients: 37 of 116 (32%) were nonadvanced adenomas and 12 of 116 (10%) advanced adenomas. LA-FOBT detected 10 of 12 (83%) advanced adenomas showing a sensitivity, specificity, positive predictive value, and negative predictive value of 83, 91, 53, and 98%, respectively. In patients with positive LA-FOBT, 1.9 colonoscopies were necessary for detecting one advanced adenoma, whereas in case of not performing this test 10 colonoscopies would be needed. Overall, approximately 80% of screening colonoscopies could be precluded using a LA-FOBT.
CONCLUSION: One-time screening with LA-FOBT successfully detects advanced colorectal adenomas and may save unnecessary colonoscopies in first-degree relatives of patients with CRC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307978     DOI: 10.1097/MEG.0b013e3283293797

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer: A Meta-analysis.

Authors:  Anastasia Katsoula; Paschalis Paschos; Anna-Bettina Haidich; Apostolos Tsapas; Olga Giouleme
Journal:  JAMA Intern Med       Date:  2017-08-01       Impact factor: 21.873

2.  Colorectal Cancer Screening in the Non-Syndromic Familial Risk Population: Is It Time to Revise the Clinical Guidelines?

Authors:  Enrique Quintero; Antonio Z Gimeno-García
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

3.  Evaluation of fecal immunochemical tests for colorectal cancer screening.

Authors:  Jeanette M Daly; Camden P Bay; Barcey T Levy
Journal:  J Prim Care Community Health       Date:  2013-05-12

4.  Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study.

Authors:  Jochim S Terhaar sive Droste; Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Vincent A Steeman; Usha Coblijn; Lisette van der Eem; Ruud Duijkers; Anneke A Bouman; Gerrit A Meijer; Annekatrien C T M Depla; Pieter Scholten; Ruud J L F Loffeld; Veerle M H Coupé; Chris J J Mulder
Journal:  BMC Gastroenterol       Date:  2012-07-24       Impact factor: 3.067

5.  Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test.

Authors:  O Otero-Estévez; L De Chiara; F J Rodríguez-Berrocal; M Páez de la Cadena; J Cubiella; I Castro; C Gonzalez-Mao; V Hernandez; V S Martínez-Zorzano
Journal:  Br J Cancer       Date:  2014-12-02       Impact factor: 7.640

6.  Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.

Authors:  Jayne Digby; Shirley Cleary; Lynne Gray; Pooja Datt; David R Goudie; Robert J C Steele; Judith A Strachan; Adam Humphries; Callum G Fraser; Craig Mowat
Journal:  United European Gastroenterol J       Date:  2020-03-16       Impact factor: 4.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.